- Bio-Path BPTH shares are trading higher Wednesday after the company announced it received a third U.S. patent grant related to the manufacture of its platform technology.
- Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease.
- Bio-Path shares traded up 150.19% to $13.01 at the time of publication. The stock has a 52-week high of $24.34 and a 52-week low of $2.92.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
